96 related articles for article (PubMed ID: 28533226)
1. IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2
Reinholz MM; Chen B; Dueck AC; Tenner K; Ballman K; Riehle D; Jenkins RB; Geiger XJ; McCullough AE; Perez EA
Clin Cancer Res; 2017 Aug; 23(15):4203-4211. PubMed ID: 28533226
[No Abstract] [Full Text] [Related]
2. Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis.
Joehlin-Price AS; Stephens JA; Zhang J; Backes FJ; Cohn DE; Suarez AA
Cancer Epidemiol Biomarkers Prev; 2016 Mar; 25(3):438-45. PubMed ID: 26682991
[TBL] [Abstract][Full Text] [Related]
3. Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer.
Schott AF; Goldstein LJ; Cristofanilli M; Ruffini PA; McCanna S; Reuben JM; Perez RP; Kato G; Wicha M
Clin Cancer Res; 2017 Sep; 23(18):5358-5365. PubMed ID: 28539464
[No Abstract] [Full Text] [Related]
4. Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma.
Field KM; King MT; Simes J; Espinoza D; Barnes EH; Sawkins K; Rosenthal MA; Cher L; Hovey E; Wheeler H; Nowak AK
J Neurooncol; 2017 Jul; 133(3):623-631. PubMed ID: 28534153
[TBL] [Abstract][Full Text] [Related]
5. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Stebbing J; Baranau Y; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskii D; Pikiel J; Eniu A; Komov D; Morar-Bolba G; Li RK; Rusyn A; Lee SJ; Lee SY; Esteva FJ
Lancet Oncol; 2017 Jul; 18(7):917-928. PubMed ID: 28592386
[TBL] [Abstract][Full Text] [Related]
6. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.
Gligorov J; Curigliano G; Müller V; Knoop A; Jenkins V; Verma S; Osborne S; Lauer S; Machackova Z; Fallowfield L; Pivot X
Breast; 2017 Aug; 34():89-95. PubMed ID: 28549309
[TBL] [Abstract][Full Text] [Related]
7. First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.
Rier HN; Levin MD; van Rosmalen J; Bos MMEM; Drooger JC; de Jong P; Portielje JEA; Elsten EMP; Ten Tije AJ; Sleijfer S; Jager A
Oncologist; 2017 Aug; 22(8):901-909. PubMed ID: 28533475
[TBL] [Abstract][Full Text] [Related]
8. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Cortés J; Rugo HS; Awada A; Twelves C; Perez EA; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; O'Shaughnessy J
Breast Cancer Res Treat; 2017 Sep; 165(2):329-341. PubMed ID: 28612225
[TBL] [Abstract][Full Text] [Related]
9. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
10. Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial.
Thomas JSJ; Provenzano E; Hiller L; Dunn J; Blenkinsop C; Grybowicz L; Vallier AL; Gounaris I; Abraham J; Hughes-Davies L; McAdam K; Chan S; Ahmad R; Hickish T; Houston S; Rea D; Caldas C; Bartlett JM; Cameron DA; Hayward RL; Earl HM
Mod Pathol; 2017 Aug; 30(8):1069-1077. PubMed ID: 28548129
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-1 signaling is responsible for cathepsin G-induced aggregation of breast cancer MCF-7 cells.
Morimoto-Kamata R; Yui S
Cancer Sci; 2017 Aug; 108(8):1574-1583. PubMed ID: 28544544
[TBL] [Abstract][Full Text] [Related]
12. Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.
Caballero I; Aira LE; Lavastida A; Popa X; Rivero J; González J; Mesa M; González N; Coba K; Lorenzo-Luaces P; Wilkinson B; Santiesteban Y; Santiesteban Y; Troche M; Suarez E; Crombet T; Sánchez B; Casacó A; Macías A; Mazorra Z
Front Pharmacol; 2017; 8():263. PubMed ID: 28539888
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
Lazaro Cebas A; Cortijo Cascajares S; Pablos Bravo S; Del Puy Goyache Goñi M; Gonzalez Monterrubio G; Perez Cardenas MD; Ferrari Piquero JM
J BUON; 2017; 22(2):334-339. PubMed ID: 28534353
[TBL] [Abstract][Full Text] [Related]
14. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).
Goldstein LJ; Zhao F; Wang M; Swaby RF; Sparano JA; Meropol NJ; Bhalla KN; Pellegrino CM; Katherine Alpaugh R; Falkson CI; Klein P; Sledge GW
Breast Cancer Res Treat; 2017 Sep; 165(2):375-382. PubMed ID: 28623430
[TBL] [Abstract][Full Text] [Related]
15. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Cameron D; Morden JP; Canney P; Velikova G; Coleman R; Bartlett J; Agrawal R; Banerji J; Bertelli G; Bloomfield D; Brunt AM; Earl H; Ellis P; Gaunt C; Gillman A; Hearfield N; Laing R; Murray N; Couper N; Stein RC; Verrill M; Wardley A; Barrett-Lee P; Bliss JM;
Lancet Oncol; 2017 Jul; 18(7):929-945. PubMed ID: 28600210
[TBL] [Abstract][Full Text] [Related]
16. T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial.
Okines AF
Rev Recent Clin Trials; 2017; 12(3):216-222. PubMed ID: 28552047
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer.
Arif Harahap W; Ramadhan ; Khambri D; Haryono S; Dana Nindrea R
Asian Pac J Cancer Prev; 2017 Apr; 18(4):1151-1156. PubMed ID: 28548467
[TBL] [Abstract][Full Text] [Related]
18. Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy.
Montagna E; Vingiani A; Maisonneuve P; Cancello G; Contaldo F; Pruneri G; Colleoni M
Breast; 2017 Aug; 34():83-88. PubMed ID: 28544923
[TBL] [Abstract][Full Text] [Related]
19. Human Hairless Protein Roles in Skin/Hair and Emerging Connections to Brain and Other Cancers.
Maatough A; Whitfield GK; Brook L; Hsieh D; Palade P; Hsieh JC
J Cell Biochem; 2018 Jan; 119(1):69-80. PubMed ID: 28543886
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
